

Rexahn, Haichang collaborate for developing liver cancer treatment

09 February 2018 | News

Any clinical trials conducted by Haichang will be designed to meet both U.S. and Chinese regulatory requirements.



American clinical stage biopharmaceutical company Rexahn Pharmaceuticals, Inc. has entered into collaboration with China based Zhejiang Haichang Biotechnology Co., Ltd., to develop RX-0201 (Archexin) for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.

As per the collaboration, Haichang will develop a nano-liposomal formulation of RX-0201 using its proprietary QTsome technology and conduct certain pre-clinical and clinical activities through completion of a Phase IIa proof-of-concept clinical trial for the treatment of HCC.

Any clinical trials conducted by Haichang will be designed to meet both U.S. and Chinese regulatory requirements. Haichang will fund all research and development activities through completion of the Phase IIa clinical trial.

The parties will share in an agreed ratio downstream licensing fees and royalties paid by third parties in connection with the further development and commercialization of the nano-liposomal formulation of RX-0201 for the treatment of HCC.